Up until recently, the stock has been a chronic underperformer.

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The ...

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...

They aren't just "pandemic stocks." ...

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC ...

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income ...

Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical ...

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC ("Tutanota") to purchase up to ...

Shares of Valneva VALN tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which ...

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 70% efficacy. The trial did ...

In the closing of the recent trading day, Pfizer (PFE) stood at $26.97, denoting a -1.61% move from the preceding trading day ...